(Q28588849)

31 January 2017

title

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice (English)

1 reference

Proprotein convertase subtilisin/kexin type 9

31 January 2017

main subject

1 reference

GOA release 2020-03-11

1 reference

Mark J. Graham

1

1 reference

31 January 2017

Kristina M. Lemonidis

2

1 reference

31 January 2017

Charles P. Whipple

3

1 reference

31 January 2017

Amuthakannan Subramaniam

4

1 reference

31 January 2017

Brett P. Monia

5

1 reference

31 January 2017

Stanley T. Crooke

6

1 reference

31 January 2017

Rosanne M. Crooke

7

1 reference

31 January 2017

publication date

1 April 2007

1 reference

Journal of Lipid Research

31 January 2017

published in

1 reference

31 January 2017

volume

48

1 reference

31 January 2017

issue

4

1 reference

31 January 2017

page(s)

763–767

1 reference

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C600025-JLR200

10.1194/JLR.C600025-JLR200

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017